Free Trial
NASDAQ:KZR

Kezar Life Sciences (KZR) Stock Price, News & Analysis

Kezar Life Sciences logo
$3.92 +0.03 (+0.77%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$3.92 +0.00 (+0.13%)
As of 10/3/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kezar Life Sciences Stock (NASDAQ:KZR)

Advanced

Key Stats

Today's Range
$3.79
$4.00
50-Day Range
$3.59
$4.36
52-Week Range
$3.56
$9.18
Volume
53,832 shs
Average Volume
40,115 shs
Market Capitalization
$28.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Hold

Company Overview

Kezar Life Sciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
56th Percentile Overall Score

KZR MarketRank™: 

Kezar Life Sciences scored higher than 56% of companies evaluated by MarketBeat, and ranked 505th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Kezar Life Sciences has a consensus price target of $9.00, representing about 129.6% upside from its current price of $3.92.

  • Amount of Analyst Coverage

    Kezar Life Sciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Kezar Life Sciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Kezar Life Sciences are expected to decrease in the coming year, from ($4.39) to ($8.31) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kezar Life Sciences is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kezar Life Sciences is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kezar Life Sciences has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Kezar Life Sciences' valuation and earnings.
  • Percentage of Shares Shorted

    12.21% of the float of Kezar Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kezar Life Sciences has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Kezar Life Sciences has recently decreased by 4.69%, indicating that investor sentiment is improving.
  • Dividend Yield

    Kezar Life Sciences does not currently pay a dividend.

  • Dividend Growth

    Kezar Life Sciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.21% of the float of Kezar Life Sciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Kezar Life Sciences has a short interest ratio ("days to cover") of 15.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Kezar Life Sciences has recently decreased by 4.69%, indicating that investor sentiment is improving.
    • Insider Buying vs. Insider Selling

      In the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      10.40% of the stock of Kezar Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

    • Read more about Kezar Life Sciences' insider trading history.
    Receive KZR Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    KZR Stock News Headlines

    Stunning new initiative unfolding in the White House?
    what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
    Kezar Life Sciences Says FDA Lifts Clinical Hold
    See More Headlines

    KZR Stock Analysis - Frequently Asked Questions

    Kezar Life Sciences' stock was trading at $6.72 at the start of the year. Since then, KZR shares have decreased by 41.7% and is now trading at $3.92.

    Kezar Life Sciences, Inc. (NASDAQ:KZR) announced its quarterly earnings results on Wednesday, August, 13th. The company reported ($1.87) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $0.28.

    Kezar Life Sciences shares reverse split on Wednesday, October 30th 2024.The 1-10 reverse split was announced on Monday, October 28th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

    Kezar Life Sciences (KZR) raised $70 million in an IPO on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO.

    Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Kezar Life Sciences investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT) and Zomedica (ZOM).

    Company Calendar

    Last Earnings
    8/13/2025
    Today
    10/04/2025
    Next Earnings (Estimated)
    11/11/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:KZR
    CIK
    1645666
    Fax
    N/A
    Employees
    60
    Year Founded
    2015

    Price Target and Rating

    High Price Target
    $9.00
    Low Price Target
    $9.00
    Potential Upside/Downside
    +129.6%
    Consensus Rating
    Hold
    Rating Score (0-4)
    2.00
    Research Coverage
    4 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($9.69)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$83.74 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -63.51%
    Return on Assets
    -52.13%

    Debt

    Debt-to-Equity Ratio
    0.03
    Current Ratio
    7.29
    Quick Ratio
    7.29

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $16.02 per share
    Price / Book
    0.24

    Miscellaneous

    Outstanding Shares
    7,323,000
    Free Float
    6,561,000
    Market Cap
    $28.71 million
    Optionable
    Not Optionable
    Beta
    0.62

    Social Links

    5G Stocks: The Path Forward is Profitable Cover

    Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

    Get This Free Report

    This page (NASDAQ:KZR) was last updated on 10/4/2025 by MarketBeat.com Staff
    From Our Partners